Grady Alice M, Bryant Jamie, Carey Mariko L, Paul Christine L, Sanson-Fisher Rob W, Levi Christopher R
Priority Research Centre for Health Behaviour, Hunter Medical Research Institute (HMRI), University of Newcastle, Callaghan, NSW, 2308, Australia.
Department of Neurology, John Hunter Hospital, New Lambton, NSW, 2305, Australia.
BMC Res Notes. 2015 Jun 26;8:267. doi: 10.1186/s13104-015-1242-5.
Emergency department staff play a crucial role in the triage of stroke patients and therefore the capacity to deliver time-dependent treatments such as tissue Plasminogen Activator. This study aimed to identify among emergency physicians, (1) rates of agreement with evidence supporting tissue Plasminogen Activator use in acute stroke care; and (2) individual and hospital factors associated with high agreement with evidence supporting tissue Plasminogen Activator use.
Australian fellows and trainees of the Australasian College for Emergency Medicine were invited to complete an online cross-sectional survey assessing perceptions of tissue Plasminogen Activator use in acute stroke. Demographic and hospital characteristics were also collected.
429 Australasian College for Emergency Medicine members responded (13% response rate). Almost half (47.2%) did not agree with any statements regarding the benefits of tissue Plasminogen Activator use for acute stroke. Perceived routine administration of tissue Plasminogen Activator by the head of respondents' emergency department was significantly associated with high agreement with the evidence supporting tissue Plasminogen Activator use in acute stroke.
Agreement with evidence supporting tissue Plasminogen Activator use in acute stroke is not high among responding Australian emergency physicians. In order for tissue Plasminogen Activator treatment to become widely accepted and adopted in emergency settings, beliefs and attitudes towards treatment need to be in accordance with clinical practice guidelines.
急诊科工作人员在中风患者的分诊中发挥着关键作用，因此具备提供诸如组织型纤溶酶原激活剂等时间依赖性治疗的能力。本研究旨在确定急诊医生中：（1）与支持在急性中风治疗中使用组织型纤溶酶原激活剂的证据的一致率；以及（2）与高度认同支持使用组织型纤溶酶原激活剂的证据相关的个人和医院因素。
邀请澳大利亚急诊医学学院的研究员和实习生完成一项在线横断面调查，评估对急性中风中使用组织型纤溶酶原激活剂的看法。还收集了人口统计学和医院特征信息。
429名澳大利亚急诊医学学院成员做出了回应（回应率为13%）。几乎一半（47.2%）的人不同意任何关于使用组织型纤溶酶原激活剂治疗急性中风的益处的陈述。受访者急诊科主任对组织型纤溶酶原激活剂的常规使用认知与高度认同支持在急性中风中使用组织型纤溶酶原激活剂的证据显著相关。
在做出回应的澳大利亚急诊医生中，对支持在急性中风中使用组织型纤溶酶原激活剂的证据的认同度不高。为了使组织型纤溶酶原激活剂治疗在急诊环境中得到广泛接受和采用，对治疗的信念和态度需要符合临床实践指南。
Zotero 插件